2.04
+9.09%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Foghorn Therapeutics
From its filings with the US Securities and Exchange Commission
Foghorn Therapeutics is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker FHTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $30.9m and a net loss of $74.3m. At that date it held total assets of $198.1m and shareholders' equity of −$108.5m.
Foghorn is a clinical stage, precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system, an untapped opportunity for therapeutic intervention in oncology and with potential in a wide spectrum of other diseases, including immunology and inflammation.
The chromatin regulatory system orchestrates gene expression—the turning on and off of genes—which is fundamental to how all our cells function. The chromatin regulatory system is implicated in approximately 50 percent of all cancers, and understanding how this system works could lead to an entirely new class of precision medicines. To our knowledge, we are the only company with the ability to study and target the chromatin regulatory system at scale, in context, and in an integrated way.
Our proprietary Gene Traffic Control® platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within this system. We have developed unique capabilities that have yielded new insights and scalability in drugging this new, previously untapped and promising area.
Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Oct 2020
- Employees
- 106
- Website
- foghorntx.com ↗
- Head office
- 500 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Adrian GottschalkPresident, Chief Executive Officer, Director, since 2017$1.6m
- Mr. Kristian HumerChief Financial Officer$1.9m
- Mr. Carlos CostaChief People Officer
- Mr. Steven BellonChief Scientific Officer$1.2m
- Mr. Michael LaCasciaChief Legal Officer$2.0m
- Dr. Alfonso Quints-CardamaChief Medical Officer$1.8m
- Dr. Anna RivkinChief Business Officer$1.5m
- Dr. Scott BillerIndependent Director$110,447
- Dr. Douglas ColeIndependent Director$149,447
- Mr. Stuart DutyIndependent Director
- Dr. Niel GallagherIndependent Director
- Dr. Adm. Balkrishan GillIndependent Director$123,947
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 28
- Environment
- 32
- Social
- 22
- Governance
- 31
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Foghorn Therapeutics' Gene Traffic Control platform enables integrated chromatin regulatory system understanding for drug discovery.
- FHD-286 is in Phase I trials for metastatic uveal melanoma and AML with two separate studies underway.
- FHD-609, a targeted protein degrader, is in Phase I for synovial sarcoma treatment development.
Weaknesses
- The company has 106 employees, which is below the industry average for biotech firms.
- Foghorn Therapeutics is a development stage company with no approved drugs yet.
- The firm's IPO in 2020 has not yet led to commercial product revenue generation.
Opportunities
- The biotechnology sector in the US shows strong growth potential for innovative drug platforms.
- Oncology and autoimmune disease therapeutic areas present significant market opportunities.
- The chromatin regulatory system research could expand into neurology and virology applications.
Threats
- Biopharmaceutical companies face high R&D costs and regulatory hurdles in drug development.
- Competition in the oncology drug market is intensifying with multiple new entrants.
- Clinical trial failures could delay or halt development of FHD-286 and FHD-609.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.